GlaxoSmithKline faces Chinese patent challenge.

Investors Chronicle, August, 2004

A group of Chinese generic drug manufacturers, believed to include Shanghai Sunve and Chongqing Taiji, are to dispute GlaxoSmithKline's patent for diabetes drug Avandia. A State Intellectual Property Office hearing is set for 18 August - analysts think China could face international trade sanctions as a result.

Analysts warn that China - already criticised for allowing software piracy - could face an international clampdown. "This blatant disregard for intellectual property flies in the face of China's international obligations," says Navid Malik of broker Williams de Broe. "It's a World Trade Organisation issue and could result in trade sanctions." Pfizer's patent for Viagra was also recently overturned by China.

The Chinese Avandia market is...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here